| (Values in U.S. Thousands) | Sep, 2016 | Jun, 2016 | Mar, 2016 | Dec, 2015 | Sep, 2015 |
| Sales | -9,999,000 | 32,050 | 27,470 | 24,670 | 25,790 |
| Sales Growth | -31,298.13% | +16.67% | +11.35% | -4.34% | +10.54% |
| Net Income | -9,999,000 | -14,020 | -41,590 | -17,000 | -14,590 |
| Net Income Growth | -71,219.54% | +66.29% | -144.65% | -16.52% | -4.59% |
Raptor Pharmaceutica (RPTP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Raptor Pharmaceutical Corp. is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. Raptor focuses on underserved patient populations where it can have the greatest potential impact. Raptor currently has product candidates in clinical development designed to treat nephropathic cystinosis, non-alcoholic steatohepatitis (`NASH`), Huntington's Disease (`HD`), aldehyde dehydrogenase (`ALDH2`) deficiency, and a non-opioid solution designed to treat chronic pain and potentially thrombotic disorder. The company's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein (`RAP`) and related proteins that are designed to target cancer, neurodegenerative disorders and infectious diseases.
Fiscal Year End Date: 12/31